Utrogestan Suppository 200mg (Progesterone (Micronized))

Adult dosage

For administration, insert the capsule deep into the vagina. The recommended dose is 200mg~400mg per dose. If necessary, use an applicator. The dose may be increased depending on the patient's response. Oocyte donation: Administer 100mg once daily on menstrual cycle days 13 and 14, then 100mg twice daily from cycle day 15 through day 25. If pregnancy is diagnosed on day 26, insert 100mg deep into the vagina in the morning and evening, or 200mg once daily. Increase the dose by 100mg per day each week, up to a maximum of 600mg per day in 3 divided doses, and administer for 60 days. In vitro fertilization: Administer 600mg per day in 3 divided doses from the day of the hCG injection until up to 12 weeks of pregnancy. Miscarriage: Treatment should be started at the first sign of vaginal bleeding in early pregnancy. Administer 400mg twice daily until 16 weeks of pregnancy.

This medication should be discontinued immediately if there is a suspicion of thromboembolic disease. Intravaginal administration is only possible during the first 4 months of pregnancy and is not used as a treatment for threatened preterm labor. Individuals allergic to any of the components of this medication or those with severe liver dysfunction should not use it. Patients with liver or biliary diseases, breast cancer, or malignant tumors of the reproductive organs should also avoid administration. During treatment, close monitoring for irregular vaginal bleeding, depressive symptoms, and symptoms of thrombosis is necessary. This medication may cause fluid retention, so caution should be exercised in patients with epilepsy, migraine, asthma, or heart and kidney diseases. Do not use concurrently with other intravaginal treatments, and ensure a minimum 6-hour interval between administrations. Caution is required when using this medication with barbiturates, antibiotics, cyclosporine, etc., due to potential drug interactions. Although safety for the fetus has been reported especially during early pregnancy in pregnant women, there may be liver-related side effects when administered during the 4th to 9th months of pregnancy. It is advisable not to administer to breastfeeding women if possible, and any adverse reactions should be reported to a doctor immediately. In the case of overdose, discontinue use immediately and seek appropriate treatment based on the symptoms.

• local irritation
• drowsiness
• dizziness
• shortened menstrual cycle
• unexpected bleeding
• changes in menstrual cycle
• amenorrhea
• sleepiness
• edema
• convulsions

This medication should be stored in a tightly closed container that is airtight, at room temperature between 1°C and 30°C. Proper storage will help maintain the efficacy of the medication.

Appearance

An oval-shaped suppository filled with a homogeneous white to off-white emulsion.

Package unit

15 pcs/PTP (7 pcs/PTP + 8 pcs/PTP)